meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
Conditions: Peritoneal Dialysis Complication; End Stage Kidney Disease; Sodium-glucose Co-transporter-2 Inhibitors; Kidney Dysfunction; Residual Kidney Function Intervention: Drug: Empagliflozin 25 MG Sponsor: University Health Network, Toronto Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Dialysis | Peritoneal Dialysis | Research | SGLT2 Inhibitors | Sodium | Urology & Nephrology